A*STAR's GIS Collaborates with GSK to Further Research on Lung Cancer
News Jan 31, 2013
In a latest boost to A*STAR's collaborations with the industry, Dr Bing LIM, Associate Director of Cancer Stem Cell Biology, and Senior Group Leader at the Genome Institute of Singapore (GIS), was recently awarded a GlaxoSmithKline (GSK) grant under the Academic Centre of Excellence (ACE) to further his research on lung cancer at the GIS.
This partnership between GIS and GSK, a multinational pharmaceutical, biologics, vaccines and consumer healthcare company which administers the ACE in Singapore, will significantly advance both organizations' joint efforts towards finding a cure for the disease.
The central goal of this grant awarded to GIS, worth SGD$350,000, is the identification of new diagnostic and therapeutic targets for cancer, and the initiation of a commit-to-target (C2T) milestone in GSK discovery. A three-pronged approach will be adopted in order to achieve this.
Leveraging on GIS' successes in identifying and characterizing lung cancer tumour initiating cells, and hence allowing for the identification of new diagnostic and therapeutic targets in lung cancer, the first of the three-pronged approach is to fully validate these targets as candidates for discovery initiation, focusing on those that are amenable to bio-therapeutics.
The second stage of the grant will focus on using high-throughput sequencing technologies to sequence the lung cancer cells and identify unique and novel variant tumors markers, which could be used as diagnostic and therapeutic targets in cancers.
The third stage involves the full characterization of monoclonal antibodies that have been generated by GIS against lung cancer cells that are highly enriched for cancer tumor initiating cells.
Dr Bing LIM said, "This collaboration with GSK provides a great opportunity for both parties to learn what the most effective way is for industry and academic research to join forces in the constantly changing landscape of scientific paradigm, biomedical technology and health care goals."
Executive Director of GIS, Prof NG Huck Hui said, "Prof Bing Lim's lab is doing cutting-edge research in lung cancer initiating cells and the award of this ACE grant is a clear endorsement of the translational value of his research. This is an exemplar of how world class research done at the Biopolis is attracting industry interest and building strategic alliance."
Dr Benjamin SEET, Executive Director of the Biomedical Research Council at A*STAR added, "This partnership is an example of the value proposition we seek to create here in Biopolis. It brings together a leading scientist with a pharmaceutical company, with the aim of taking a scientific discovery closer to the clinic, and finding new cures for a disease that is currently difficult to treat".
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Understanding the Cellular Systems that Hold Back the Spread of CancerNews
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018